The authors directly compared the iPSC-derived CAR T cells with TCR-αβ and TCR-γδ peripheral blood lymphocytes from the same donor and transduced with the same CAR and demonstrated that the iPSC-derived CAR T cells showed a similar anti-cancer activity as the CAR TCR-γδ cells in an immunodeficient mouse xenograft tumor model using the CD19+ Raji human Burkitt lymphoma cell line (55). Here, CD19 is linked to neoplasm.